HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
MDT
Medtronic plc
MDT's fundamentals are strong: it turned 16% of its revenue into free cash flow and revenue grew 9.8%. At 25x earnings, it's trading in line with its usual 27x. Analysts expect earnings growth.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
MDT Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| Strong | |
| Stable |
MDT's revenue, profitability and cash flow are currently healthy, and its balance sheet is stable.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
MDT PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 16x | $101 | — |
| Cheap | 24x | $98.52 | -2.4% |
| Current | 25x | $101 | — |
| Fair | 27x | $111 | +9.9% |
| Expensive | 33x | $135 | +34% |
Historical ranges are pointers, not guarantees.
MDT's PE is in its cheap range at 25x. If earnings grow as analysts expect, today's price would be 16x next year's earnings.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
MDT Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Growth | |
| Growth | |
| Improving | |
| Moderate | |
| High |
MDT has the edge over HIMS on the outlook, with more favorable earnings and profitability expectations.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
MDT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $6.16 | +52% |
| Q3 2026 | $4.06 | +12% |
| Q2 2026 | $3.73 | +3.3% |
| Q1 2026 | $3.58 | +8.5% |
| Q4 2025 | $3.70 | +13% |
| Q3 2025 | $3.62 | +22% |
| Q2 2025 | $3.61 | +31% |
| Q1 2025 | $3.30 | +5.1% |
| Q4 2024 | $3.28 | +6.8% |
MDT has the edge over HIMS on earnings quality, reporting a profit while its opponent remains loss making.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over MDT on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
MDT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $9.8B | +14% |
| Q2 2026 | $9.8B | +9.9% |
| Q1 2026 | $9B | +8.7% |
| Q4 2025 | $9B | +6.6% |
| Q3 2025 | $8.6B | +8.4% |
| Q2 2025 | $8.9B | +3.9% |
| Q1 2025 | $8.3B | +2.5% |
| Q4 2024 | $8.4B | +5.2% |
MDT's revenue has grown year over year for 14 quarters in a row: $9.8B last quarter, up 14% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 18% | +1.2 points |
| Q2 2026 | 19% | +3 points |
| Q1 2026 | 16% | -3.6 points |
| Q4 2025 | 19% | -0.2 points |
| Q3 2025 | 17% | +0.7 points |
| Q2 2025 | 16% | +3.8 points |
| Q1 2025 | 20% | +1.5 points |
| Q4 2024 | 19% | +2.2 points |
MDT has the edge over HIMS on profitability, with a higher operating margin.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over MDT on cash flow, with more consistent year-over-year improvement.
MDT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $1.3B | +121% |
| Q2 2026 | $2.1B | +0.8% |
| Q1 2026 | $2.3B | +9.7% |
| Q4 2025 | $457M | -18% |
| Q3 2025 | $584M | +25% |
| Q2 2025 | $2.1B | -12% |
| Q1 2025 | $2.1B | -1.5% |
| Q4 2024 | $554M | +177% |
MDT generated $6.1B in free cash flow over the past year, up 16% from the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over MDT on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
MDT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.2% | -3M shares |
| 1 year | -0.2% | -2M shares |
| 3 years | -3.7% | -48.7M shares |
| 5 years | -5.3% | -71.3M shares |
| Available history | -4.9% | -66.3M shares |
MDT has 1.3B diluted shares, about the same as a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $267M |
| Q2 2026 | $435M |
| Q1 2026 | $105M |
| Q4 2025 | $372M |
| Q3 2025 | $123M |
| Q2 2025 | $274M |
| Q1 2025 | $181M |
| Q4 2024 | $288M |
MDT spent $1.2B buying back its own shares over the past year, up 36% from the year before.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
MDT Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 2.7x | Moderate |
| Q2 2026 | 2.8x | Moderate |
| Q1 2026 | 3.0x | Moderate |
| Q4 2025 | 3.0x | Elevated |
| Q3 2025 | 3.0x | Elevated |
| Q2 2025 | 3.0x | Moderate |
| Q1 2025 | 3.1x | Elevated |
| Q4 2024 | 3.4x | Elevated |
MDT's net debt is about 2.7 years of its operating earnings (EBITDA), down from 3.0 years a year ago.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
MDT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 65.9 | Neutral |
| Stochastic | 81.3 | Overbought |
MDT's weekly RSI is 66 (neutral) and its Stochastic is 81 (overbought).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
MDT PE vs Healthcare Sector
| Metric | MDT | Sector median | Relative |
|---|---|---|---|
| PE | 25x | 26x | 3.8% below |
| PE % | 22 | 29 | 7 pts below |
MDT is trading at 25x earnings, in line with the Healthcare sector's median of 26x.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
MDT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $94.1 | 7.3% above |
| 20 week MA | $90.6 | 11% above |
| 50 week MA | $90.0 | 12% above |
| 100 week MA | $89.9 | 12% above |
| 200 week MA | $86.6 | 17% above |
MDT has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
MDT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $113.4 | $114.0 | +0.6% |
| 2021 | $114.0 | $102.9 | -9.8% |
| 2022 | $102.9 | $77.5 | -25% |
| 2023 | $77.5 | $82.4 | +6.3% |
| 2024 | $82.4 | $80.7 | -2% |
| 2025 | $80.7 | $96.5 | +20% |
| 2026 YTD | $96.5 | $101.0 | +4.6% |
MDT has the edge over HIMS on returns for 2026, with the stronger performance.